Enasidenib mesylate is a Small Molecule owned by Bristol-Myers Squibb, and is involved in 9 clinical trials, of which 1 was completed, and 8 are ongoing.
Enasidenib mesylate is a selective, potent inhibitor of the mutated IDH2 protein. AG-221 (IDH-2) catalyze the oxidative decarboxylation of isocitrate to 2-oxoglutarate. IDH mutations induce DNA hypermethylation which is an epigenetic phenomenon in many cancer cells, and impair differentiation in hematopoietic cells. Oncometabolite 2-hydroxyglutarates (2HG) high levels may lead to the epigenetic rewiring of cells and tumorigenesis. The drug candidate act by disrupting certain enzymes which are responsible for any of glycolysis, fatty acid metabolism and autophagy which play critical role in cancer metabolism. The drug candidate produces therapeutic action by Inhibition of IDH-2.
The revenue for Enasidenib mesylate is expected to reach a total of $3.3bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Enasidenib mesylate NPV Report.
Enasidenib mesylate Overview
Enasidenib mesylate (CC-90007, AG-221, Idhifa) is an anti cancer agent. It is formulated as film coated tablets and tablets for oral route of administration. Idhifa is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation.
It is under development for the treatment of clonal cytopenia of undetermined significance (CCUS), hematologic malignancies including untreated or relapsed and refractory AML (in the EU), and myelodysplastic syndrome (MDS), relapsed/ refractory multiple myeloma, chronic myelomonocytic leukemia (CMML), myeloproliferative neoplasm solid tumors, hepatic impairment.
It was also under development for non-Hodgkins T cell lymphoma, myeloproliferative disorders, angioimmunoblastic T-cell lymphoma (AITL), solid tumor and hematological tumor, type II D-2-hydroxyglutaric aciduria.
Bristol-Myers Squibb Overview
Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.
The company reported revenues of (US Dollars) US$46,385 million for the fiscal year ended December 2021 (FY2021), an increase of 9.1% over FY2020. The operating profit of the company was US$8,615 million in FY2021, compared to an operating loss of US$6,847 million in FY2020. The net profit of the company was US$6,994 million in FY2021, compared to a net loss of US$9,015 million in FY2020. The company reported revenues of US$11,218 million for the third quarter ended September 2022, a decrease of 5.6% over the previous quarter.
Quick View – Enasidenib mesylate
|Highest Development Stage|